article thumbnail

Adjuvant alectinib found to be effective in early-stage ALK-positive non-small cell lung cancer

Hospital Pharmacy Europe

The use of adjunctive alectinib reduced disease recurrence in the early setting for people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) compared to platinum-based chemotherapy, its manufacturer Roche has announced. The OS data were immature at the time of the interim analysis.

article thumbnail

Rucaparib receives positive CHMP opinion for advanced ovarian cancer

Hospital Pharmacy Europe

Suitable for all women with advanced ovarian cancer, regardless of BRCA mutation status, who have responded to first-line platinum-based chemotherapy, rucaparib (brand name Rubraca) is a poly-ADP ribose polymerase (PARP) inhibitor. Dr Rebecca Kristeleit, consultant medical oncologist and adjunct reader at Guy’s and St.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Gilead claims first CAR-T approval for leukaemia in older adults

pharmaphorum

The European Commission has approved Tecartus (brexucabtagene autoleucel) for adults aged 26 and over with relapsed or refractory B-cell precursor ALL, a patient population not covered by the label for Novartis’ CD19 CAR-T Kymriah (tisagenlecleucel), which covers paediatric and young adult patients up to age 25.

article thumbnail

Zanubrutinib receives approval in Europe for follicular lymphoma

Hospital Pharmacy Europe

Some 217 patients with R/R follicular lymphoma who had received at least two prior lines of systemic therapy were included in the global, randomised, open-label study. Brukinsa is a chemotherapy-free, oral treatment option that can be a practice-changing option for eligible patients with relapsed or refractory follicular lymphoma.’

article thumbnail

MHRA approves adagrasib for NSCLC after earlier EMA rejection

Hospital Pharmacy Europe

Adagrasib is a monotherapy indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy.

article thumbnail

Enhancing collaboration to optimise medication therapy in older adults with cancer: a position paper from SOFOG-SFPO

Hospital Pharmacy Europe

4,5 Polypharmacy – daily use of five or more drugs – is common in these patients and increases the risk of DRPs, which can result in adverse outcomes such as postoperative complications, chemotherapy toxicities and functional decline. 10,11 This can be due to side effects of chemotherapy or the addition of certain supportive care medications.

article thumbnail

How A Possessive and Overstocking Atmosphere Resulted In Hoarding Between Departments

The Happy PharmD

I think I first realized it when I was working at my first hospital. My hospital had a unique financial blueprint. It seemed that they paid bills when they wanted to Many companies didn’t like this arrangement and wouldn’t do business with our hospital. Possession ruled the departments of my hospital. But some did.